Negócios · 01/06/19981 min de leitura
Implantation or Injectable Dosage Form New Animal Drugs; Lufenuron Suspension
Tradução automática local · Idioma original da fonte
Resumo
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Novartis Animal Health US, Inc. The NADA provides for subcutaneous use of lufenuron suspension in cats for control of flea populations.